Brokers Issue Forecasts for Gilead Sciences FY2025 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Cantor Fitzgerald upped their FY2025 earnings per share estimates for shares of Gilead Sciences in a research note issued to investors on Wednesday, February 19th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biopharmaceutical company will post earnings of $7.98 per share for the year, up from their prior estimate of $7.24. Cantor Fitzgerald currently has a “Neutral” rating and a $80.00 target price on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.94 per share.

Several other analysts also recently weighed in on the company. Barclays upped their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. BMO Capital Markets increased their target price on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Morgan Stanley increased their target price on Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Finally, Wells Fargo & Company increased their price target on Gilead Sciences from $105.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $102.08.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $109.95 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $137.03 billion, a P/E ratio of 297.16, a PEG ratio of 0.90 and a beta of 0.18. The stock’s 50 day moving average is $95.41 and its 200 day moving average is $88.63. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $111.03.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. State Street Corp raised its position in shares of Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after acquiring an additional 841,776 shares during the period. FMR LLC raised its position in shares of Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock worth $3,724,306,000 after purchasing an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Gilead Sciences by 3.1% during the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock worth $3,293,822,000 after purchasing an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Gilead Sciences by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock worth $2,608,337,000 after purchasing an additional 749,047 shares during the last quarter. Finally, Norges Bank purchased a new stake in Gilead Sciences during the 4th quarter valued at about $1,789,254,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 713,000 shares of company stock valued at $67,945,181. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is currently 832.43%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.